CLL

Relapsed or Refactory

Criteria to qualify for study: Drug used in study:
  • —Documentation of cytogenetics or FISH with analysis for del(17p)
  • Must have at least on bi-dimensionally measurable lesion ≥ 1.5 cm.
  • — Must have had at least one prior anti-cancer treatment.

SCRI  CLL-30

A Phase 3 Study of IPI-145 versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

 

 

 

 

 

 

Criteria to qualify for study: Drug used in study:
  • CD20 positive
  • Must have at least on bi-dimensionally measurable lesion ≥ 1.5 cm.
  • Must have had at least one prior anti­cancer treatment.

SCRI  HEMREF-34

An Open-Label, Phase lb Study of IPI-145 in combination with Bendamustine, Rituximab or Bendamustine/Rituximab in Select Subjects with
Lymphoma or Chronic Lymphocytic Leukemia

 

 

 

 

 


Relapsed, Refactory or Untreated

Criteria to qualify for study: Drug used in study:
  • CDS, CD19/20, and CD23 positive
  • No more that 55% of circulating lymphocytes
  • Lymphocyte count at diagnosis must be at least 5x103/µL

 

SCRI CLL-23

A Phase lb Multlcenter Dose-Finding and Safety Study of GDC-0199 and Obinutuzumab in Patients with Relapsed or Refractory or Previously Untreated Chronic Lymphocytic Leukemia

 

 

 

 

 

 

Criteria to qualify for study: Drug used in study:
  • CD20 positive
  • Must have received at least one prior therapy

SCRI CLL-18

Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia, a Phase II Trial